Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
1. Novartis will acquire Tourmaline for $48 per share. 2. Deal values Tourmaline at approximately $1.4 billion. 3. The acquisition reflects Tourmaline's promising drug pacibekitug. 4. Transaction expected to complete in Q4 2025, subject to conditions. 5. Tourmaline will remain independent until the deal closes.